Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder.

Bobo WV, Shelton RC.

Expert Rev Neurother. 2010 Nov;10(11):1637-58. doi: 10.1586/ern.10.143. Review.

PMID:
20977322
2.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
3.

A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently.

Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C, Kujawa M, Mahmoud R.

Bipolar Disord. 2009 Dec;11(8):827-39. doi: 10.1111/j.1399-5618.2009.00761.x.

PMID:
19922552
4.
5.

Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder.

Han C, Lee MS, Pae CU, Ko YH, Patkar AA, Jung IK.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1219-23. Epub 2007 May 1.

PMID:
17532106
6.

Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients.

Malempati RN, Bond DJ, Yatham LN.

Int Clin Psychopharmacol. 2008 Mar;23(2):88-94. doi: 10.1097/YIC.0b013e3282f2b4c5.

PMID:
18301123
7.

Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder.

Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V.

Biol Psychiatry. 2010 Jul 15;68(2):156-62. doi: 10.1016/j.biopsych.2010.01.015. Epub 2010 Mar 15.

PMID:
20227682
8.

Long-term efficacy of risperidone long-acting injectable in bipolar disorder with psychotic features: a prospective study of 3-year outcomes.

Malempati RN, Bond DJ, Kunz M, Malemati C, Cheng A, Yatham LN.

Int Clin Psychopharmacol. 2011 May;26(3):146-50. doi: 10.1097/YIC.0b013e328343ba60.

PMID:
21372721
9.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group..

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
10.

A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.

J Clin Psychiatry. 2009 Oct;70(10):1397-406. doi: 10.4088/JCP.09m05284yel.

PMID:
19906343
11.

A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone.

Vieta E, Nieto E, Autet A, Rosa AR, Goikolea JM, Cruz N, Bonet P.

World J Biol Psychiatry. 2008;9(3):219-24. doi: 10.1080/15622970701530917.

PMID:
18609430
12.

Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Masand PS, Gupta S.

Drugs Aging. 2003;20(15):1099-110. Review.

PMID:
14651433
13.

One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study.

Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E.

Clin Schizophr Relat Psychoses. 2012 Jul;6(2):61-8. doi: 10.3371/CSRP.6.2.3.

PMID:
22776632
14.

Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.

Arunpongpaisal S, Srisurapanont M, Kongsakon R, Kitiwattanagul K, Samanwongthai U.

J Med Assoc Thai. 2010 Mar;93(3):343-50.

PMID:
20420110
15.

Explicit review of risperidone long-acting injection prescribing practice.

Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E.

J Clin Pharm Ther. 2011 Dec;36(6):651-63. doi: 10.1111/j.1365-2710.2010.01219.x. Epub 2010 Nov 5.

PMID:
22023342
16.

Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.

Keith S.

Expert Rev Neurother. 2009 Jan;9(1):9-31. doi: 10.1586/14737175.9.1.9. Review.

PMID:
19102665
17.

Role of risperidone in bipolar II: an open 6-month study.

Vieta E, Gastó C, Colom F, Reinares M, Martínez-Arán A, Benabarre A, Akiskal HS.

J Affect Disord. 2001 Dec;67(1-3):213-9.

PMID:
11869771
18.

Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.

Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R.

Pharmacopsychiatry. 2007 Nov;40(6):257-63.

PMID:
18030649
19.

A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.

Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, Rodriguez S, Gharabawi GM.

J Clin Psychiatry. 2006 Aug;67(8):1194-203.

PMID:
16965196
20.

Olanzapine: new indication. Prevention of bipolar disorder: unconvincing trials.

[No authors listed]

Prescrire Int. 2005 Aug;14(78):140-2.

PMID:
16106596

Supplemental Content

Support Center